GRAL

GRAIL Inc

124.67

Oct 20 • 3:59 PM ET +2.25 (1.84%)

124.67

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Mid NASD

Peers: GH FRNM NTRA BLLN ILMN NEO VCYT DGX TEM CAI

| Held by: VTI IWM XBI VXF IWN IBB VTWO DFAS SCHA VHT

Scroll to Statements

Index	RUT
Market Cap	5.57B
Enterprise Value	4.80B
Income	-391.59M
Sales	165.26M
Book/sh	56.93
Cash/sh	19.29
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	910
IPO	Jun 12, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	33.70
P/B	2.19
P/C	6.46
P/FCF	-
EV/EBITDA	-
EV/Sales	29.03
Quick Ratio	10.74
Current Ratio	10.95
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-9.75
EPS next Y	-10.27
EPS next Q	-2.50
EPS this Y	13.38%
EPS next Y	-6.74%
EPS next 5Y	4.27%
EPS past 3/5Y	60.02% -41.05%
Sales past 3/5Y	38.37% -
EPS Y/Y TTM	24.60%
Sales Y/Y TTM	23.07%
EPS Q/Q	19.70%
Sales Q/Q	25.72%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	3.60% 5.42%

Insider Own	5.66%
Insider Trans	-4.94%
Inst Own	85.84%
Inst Trans	5.54%
ROA	-14.12%
ROE	-16.12%
ROIC	-14.93%
Gross Margin	-36.99%
Oper. Margin	-323.02%
Profit Margin	-236.95%
SMA20	-6.30%
SMA50	24.77%
SMA200	63.36%
Trades

Shs Outstand	44.67M
Shs Float	42.14M
Short Float	19.01%
Short Ratio	8.12
Short Interest	8.01M
52W High	166.48 -25.11%
52W Low	41.50 200.41%
Volatility	8.18% 9.73%
ATR (14)	9.95
RSI (14)	52.88
Beta	2.90
Rel Volume	0.75
Avg Volume	986.35K
Volume	738,860

Perf Week	-11.17%
Perf Month	15.47%
Perf Quarter	76.44%
Perf Half Y	144.21%
Perf YTD	45.66%
Perf Year	35.73%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.38
Target Price	134.30
Prev Close	122.42
Price	124.67
Change %	1.84%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-26	Initiated	RBC Capital Mkts	Sector Perform	$84
Sep-09-26	Resumed	UBS	Buy	$105
Jun-05-26	Initiated	Goldman	Neutral	$60
Jun-02-26	Resumed	Wolfe Research	Peer Perform
Apr-10-26	Initiated	Mizuho	Neutral	$58
Mar-18-26	Upgrade	TD Cowen	Hold → Buy	$65
Feb-19-26	Initiated	TD Cowen	Hold	$114
Feb-17-26	Initiated	Robert W. Baird	Outperform	$113
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$110
Nov-12-25	Upgrade	Guggenheim	Neutral → Buy	$100
Apr-21-25	Initiated	Canaccord Genuity	Buy	$32
Nov-27-24	Initiated	Morgan Stanley	Equal-Weight	$16
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Oct-17-24	Initiated	Guggenheim	Neutral

Show Previous Ratings

Oct-05-26 04:01PM	GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 (PR Newswire) +7.55% -10.90%
Oct-01-26 05:30AM	A Cancer Test Has Investors Betting Big. But Will Insurers Pay? (The Wall Street Journal) -5.40%
Sep-30-26 08:02AM	Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next. (Investor's Business Daily)
Sep-24-26 11:23PM	MRNA On Track To Be September's No. 2 S&P 500 Stock But These 5 Smaller Health Care Names Did Even Better (Stocktwits) +15.38%
04:16PM	Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test (Investor's Business Daily)
07:23PM	Loading…
Sep-23-26 07:23PM	FDA Advisors Said It Should Approve the Grail Multicancer Blood Test (Barrons.com)
06:55PM	Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval (The Wall Street Journal)
06:49PM	The Holy Grail In Cancer? FDA Panel Backs Blood Tests. (Investor's Business Daily)
06:17PM	FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test (PR Newswire)
08:39AM	FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. (MarketWatch)
Sep-22-26 02:07AM	GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why. (TIKR)
Sep-21-26 04:50PM	GRAL Stock Clocks Best Day In Over 1.5 Years FDA Papers Lift Galleri Approval Hopes (Stocktwits) +33.68%
04:14PM	Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test (Investor's Business Daily)
11:28AM	Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA (Barrons.com)
07:06AM	FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week (Stocktwits)
04:02PM	Loading…
Sep-03-26 04:02PM	GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Aug-31-26 04:01PM	GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference (PR Newswire)
Aug-07-26 11:05AM	GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test (PR Newswire) +9.59%
Aug-06-26 08:30AM	GRAIL, Inc. Q2 2026 Earnings Call Summary (Moby) -14.53%
01:09AM	GRAIL Inc (GRAL) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Aug-05-26 04:02PM	GRAIL Reports Second Quarter 2026 Financial Results (PR Newswire)
Jul-30-26 04:01PM	GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference (PR Newswire) +12.14%
Jul-29-26 04:01PM	GRAIL to Announce Second Quarter 2026 Financial Results (PR Newswire)
Jul-27-26 04:37AM	GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL (PR Newswire)
Jul-16-26 09:00AM	Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri Multi-Cancer Early Detection Blood Test to Employer Plans (PR Newswire)
Jul-13-26 05:03AM	GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL (PR Newswire)
Jul-09-26 04:24PM	Cancer Blood Screen SPAC's Merger Is Delayed by Test's Results (Barrons.com) +8.06% -5.00%
Jul-01-26 06:02PM	When Multi-Cancer Blood Screens Could Finally Take Off (Barrons.com)
Jun-25-26 09:00AM	GRAIL Completes $110 Million Equity Financing With Samsung Entities (PR Newswire)
Jun-01-26 11:06AM	Grail Plummets On Mixed Results For Cancer-Screening Blood Test (Investor's Business Daily) -10.16%
08:00AM	Loading…
May-31-26 08:00AM	GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting (PR Newswire)
May-30-26 08:00AM	GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting (PR Newswire)
May-27-26 04:01PM	GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-26-26 04:01PM	GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
May-21-26 04:01PM	GRAIL to Present at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-05-26 04:01PM	GRAIL Reports First Quarter 2026 Financial Results (PR Newswire) +15.35%
Apr-30-26 04:01PM	GRAIL to Present at the BofA Securities 2026 Health Care Conference (PR Newswire) +9.64%
Apr-22-26 04:01PM	GRAIL to Announce First Quarter 2026 Financial Results (PR Newswire)
Apr-21-26 04:53PM	GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting (PR Newswire)
Apr-07-26 04:01PM	GRAIL Announces Integration of the Galleri Test into Epic Electronic Health Record Platform to Expand Access Nationwide (PR Newswire) -5.01%
Apr-01-26 01:09PM	Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection (PR Newswire)
Mar-18-26 09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
09:00AM	LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED (PR Newswire)
Mar-12-26 04:30PM	GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor (PR Newswire)
Mar-02-26 04:01PM	GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-27-26 12:19AM	Here's What Analysts Are Saying About Grail Inc. (GRAL) (Insider Monkey) -8.38%
Feb-26-26 05:00PM	Grail's Stock Dropped 50% on Friday. Investors Still Have High Hopes for the Biotech. (Barrons.com) +12.18%
Feb-24-26 04:02PM	GRAIL to Present at the TD Cowen 46th Annual Health Care Conference (PR Newswire) +17.01%
02:24PM	Lost Money on GRAIL, Inc. (GRAL)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Feb-23-26 09:29AM	GRAIL Stock Tumbles - National Health Service Galleri Trial To Blame (Benzinga) -14.30%
Feb-20-26 05:01PM	Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main Goal (GuruFocus.com) -50.55%
04:33PM	Stocks Settle Higher as SCOTUS Rejects President Trumps Tariffs (Barchart)
04:28PM	Stock Market Today: Nasdaq Charges Higher As Trump Announces Global Tariff; Nvidia Shares Rise (Live Coverage) (Investor's Business Daily)
04:26PM	This once-hot cancer-detection company's stock got cut in half after a failed trial (MarketWatch)
01:16PM	Why Grail Stock Has Plunged 50% Despite Earnings Beat (Barrons.com)
11:27AM	Stock Market Today: Dow Turns Higher As Supreme Court Nixes Trump Tariffs (Live Coverage) (Investor's Business Daily)
11:25AM	Stocks Rebound as Supreme Court Strikes Down President Trumps Tariffs (Barchart)
11:02AM	Supreme Court Rules Against Trump's Tariffs: These 10 Stocks Are Soaring (Benzinga)
10:34AM	Biotech Stock Plummets on Cancer Screening Trial Results (Schaeffer's Research)
09:48AM	Stock Market Today: Dow Falls On Inflation Data, Weak GDP; Trump Tariff Ruling May Be Up Next (Live Coverage) (Investor's Business Daily)
09:44AM	Grail Stock Tanks After Cancer-Screening Study (The Wall Street Journal)
08:15AM	Stock Market Today: Dow Falls Ahead Of Trump Tariff Decision; Grail Crashes After Test Results (Live Coverage) (Investor's Business Daily)
05:38AM	These Stocks Are Today's Movers: Opendoor, Nvidia, Grail, Newmont, AppLovin, and More (Barrons.com)
05:18AM	Why Grail Stock Is Sinking Friday (Benzinga)
04:57AM	Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus (Benzinga)
04:06AM	Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. (Barrons.com)
12:00AM	GRAIL Inc (GRAL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Challenges (GuruFocus.com)
Feb-19-26 09:27PM	Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Business Wire)
09:10PM	GRAIL Q4 Earnings Call Highlights (MarketBeat)
05:06PM	Grail shares plunge on mixed cancer trial data and steep losses (Investing.com)
04:02PM	GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
04:01PM	Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate (PR Newswire)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More (24/7 Wall St.)
Feb-16-26 09:00AM	GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-09-26 03:30AM	Hims & Hers Super Bowl Ad For Cancer Test Raises Questions Over Reliability (Benzinga)
Feb-06-26 05:41PM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com) +6.39%
Feb-04-26 04:09PM	Hims & Hers Scores A Cancer Deal With Grail, But Shares Reverse Lower (Investor's Business Daily) -6.20%
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
Jan-29-26 07:25PM	GRAIL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test (PR Newswire)
Jan-24-26 12:01PM	The Most Expensive Question Investors Ask (Barchart)
Jan-22-26 03:24PM	Here's Why This Exciting Healthcare Stock Popped 13% Today (Motley Fool) +14.83%
Jan-03-26 10:24AM	Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025 (MarketBeat)
Dec-28-25 10:05AM	Morgan Stanley Eyes Emerging Growth for Grail (GRAL) as Sector Valuations Reach Equilibrium (Insider Monkey)
Dec-15-25 04:01PM	GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-02-25 04:54AM	Here's Why Grail Soared, Again, in November (Motley Fool)
Dec-01-25 04:01PM	GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -10.98%
Nov-20-25 09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
Nov-19-25 10:38AM	Why GRAIL Stock Could Be Biotech's Next Big Breakout (MarketBeat) +7.99%
Nov-18-25 04:02PM	GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-17-25 07:30PM	Why Grail Stock Zoomed Nearly 7% Higher on Monday (Motley Fool) +6.67%
Nov-13-25 12:03AM	GRAIL Inc (GRAL) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-12-25 04:02PM	GRAIL Reports Third Quarter 2025 Financial Results (PR Newswire)
09:06AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AT&T, Beyond Meat, Carvana, Fortinet, Snowflake, Waste Managment and More (24/7 Wall St.)
05:25AM	Cisco Systems headlines earnings slate (MarketWatch)
03:51AM	Stock Market Today: Dow consolidates after 3-day 1,000-point surge to record high, S&P 500 and Nasdaq called higher as Treasury yields dip; Cisco earnings on tap. (MarketWatch)
Nov-06-25 06:00AM	Here's Why Grail Stock Exploded Higher by 55% in October (Motley Fool) -5.41%
Nov-04-25 04:02PM	GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference (PR Newswire) -10.15%
Oct-29-25 04:02PM	GRAIL to Announce Third Quarter 2025 Financial Results (PR Newswire) +6.97%
Oct-25-25 12:45AM	Jim Cramer on GRAIL: "Don't Call Yourself Early if You're Buying This One" (Insider Monkey)
Oct-24-25 08:12AM	Jim Cramer on GRAIL: "I'm Going to Say Absolutely Not to That One" (Insider Monkey) +8.15%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ofman Joshua J.	Chief Executive Officer	Oct 15 '26	Sale	136.85	20,000	2,736,945	342,271	Oct 16 04:50 PM
JOSHUA OFMAN	Director	Oct 15 '26	Proposed Sale	139.70	5,000	698,500		Oct 15 04:41 PM
Partridge Andrew John	Chief Growth Officer	Oct 05 '26	Sale	146.39	7,873	1,152,528	155,865	Oct 07 06:36 PM
Freidin Aaron	Chief Financial Officer	Oct 05 '26	Sale	146.39	23,619	3,457,585	225,364	Oct 07 06:36 PM
Andrew Partridge	Officer	Oct 05 '26	Proposed Sale	146.39	7,873	1,152,533		Oct 05 07:53 PM
Aaron Freidin	Officer	Oct 05 '26	Proposed Sale	146.39	23,619	3,457,600		Oct 05 07:52 PM
Freidin Aaron	Chief Financial Officer	Sep 21 '26	Sale	93.34	4,100	382,679	248,983	Sep 23 04:37 PM
Ofman Joshua J.	Chief Executive Officer	Sep 21 '26	Option Exercise	14.00	26,452	370,328	423,723	Sep 23 04:37 PM
Ofman Joshua J.	Chief Executive Officer	Sep 21 '26	Sale	97.74	61,452	6,006,378	362,271	Sep 23 04:37 PM
JOSHUA OFMAN	Director	Sep 21 '26	Proposed Sale	80.77	71,452	5,771,178		Sep 21 04:34 PM
Ofman Joshua J.	Chief Executive Officer	Aug 27 '26	Sale	85.02	5,000	425,098	397,271	Aug 31 08:07 PM
Freidin Aaron	Chief Financial Officer	Aug 27 '26	Sale	85.01	7,900	671,579	253,083	Aug 31 08:07 PM
JOSHUA OFMAN	Director	Aug 27 '26	Proposed Sale	79.59	10,000	795,900		Aug 27 04:26 PM
AARON FREIDIN	Officer	Aug 27 '26	Proposed Sale	79.59	12,000	955,080		Aug 27 04:18 PM
Partridge Andrew John	Chief Growth Officer	Jun 04 '26	Sale	61.08	1,491	91,070	163,738	Jun 05 08:16 PM
Andrew Partridge	Officer	Jun 03 '26	Proposed Sale	61.13	1,705	104,227		Jun 03 07:20 PM
Freidin Aaron	Chief Financial Officer	Apr 08 '26	Sale	49.92	45,806	2,286,526	260,669	Apr 09 06:58 PM
RAGUSA ROBERT P	Chief Executive Officer	Apr 08 '26	Sale	49.92	123,502	6,164,923	518,582	Apr 09 06:58 PM
Ofman Joshua J.	President	Apr 08 '26	Sale	49.92	61,665	3,078,169	371,216	Apr 09 06:58 PM
Aaron Freidin	Officer	Apr 03 '26	Proposed Sale	51.74	49,414	2,556,680		Apr 06 07:50 PM
Joshua Ofman	Officer	Apr 06 '26	Proposed Sale	51.74	66,522	3,441,848		Apr 06 07:49 PM
Robert Ragusa	Officer	Apr 06 '26	Proposed Sale	51.74	133,230	6,893,320		Apr 06 07:47 PM
Freidin Aaron	Chief Financial Officer	Mar 09 '26	Sale	47.89	2,492	119,340	306,475	Mar 09 09:36 PM
Freidin Aaron	Chief Financial Officer	Mar 05 '26	Sale	53.01	655	34,722	308,967	Mar 09 09:36 PM
Ofman Joshua J.	President	Mar 09 '26	Sale	47.89	2,937	140,650	432,881	Mar 09 09:36 PM
Ofman Joshua J.	President	Mar 05 '26	Sale	53.01	690	36,577	435,818	Mar 09 09:36 PM
RAGUSA ROBERT P	Chief Executive Officer	Mar 09 '26	Sale	47.89	7,461	357,296	642,084	Mar 09 09:35 PM
RAGUSA ROBERT P	Chief Executive Officer	Mar 05 '26	Sale	53.01	980	51,950	649,545	Mar 09 09:35 PM
Aaron Freidin	Officer	Mar 04 '26	Proposed Sale	51.80	3,471	179,798		Mar 05 09:12 PM
Robert Ragusa	Officer	Mar 05 '26	Proposed Sale	51.80	9,285	480,963		Mar 05 09:10 PM
Joshua J. Ofman	Officer	Mar 05 '26	Proposed Sale	51.80	3,999	207,148		Mar 05 09:09 PM
Ofman Joshua J.	President	Mar 02 '26	Sale	50.16	17,002	852,848	436,508	Mar 03 09:12 PM
Freidin Aaron	Chief Financial Officer	Mar 02 '26	Sale	50.17	9,573	480,244	309,622	Mar 03 08:45 PM
RAGUSA ROBERT P	Chief Executive Officer	Mar 02 '26	Sale	50.17	37,504	1,881,417	650,525	Mar 03 08:15 PM
Joshua J. Ofman	Officer	Mar 02 '26	Proposed Sale	53.23	18,423	980,656		Mar 02 07:07 PM
Aaron Freidin	Officer	Mar 02 '26	Proposed Sale	53.23	10,374	552,208		Mar 02 07:05 PM
Robert Ragusa	Officer	Mar 02 '26	Proposed Sale	53.23	40,641	2,163,320		Mar 02 06:59 PM
Ofman Joshua J.	President	Dec 03 '25	Sale	100.00	13,000	1,300,000	368,818	Dec 05 04:12 PM
RAGUSA ROBERT P	Chief Executive Officer	Dec 03 '25	Sale	95.24	40,000	3,809,535	688,029	Dec 05 04:12 PM
Freidin Aaron	Chief Financial Officer	Dec 03 '25	Sale	99.15	25,000	2,478,818	259,077	Dec 05 04:12 PM
AARON FREIDIN	Officer	Dec 03 '25	Proposed Sale	99.15	25,000	2,478,818		Dec 03 04:34 PM
JOSHUA J OFMAN	Officer	Dec 03 '25	Proposed Sale	100.00	13,000	1,300,000		Dec 03 04:33 PM
ROBERT P RAGUSA	Officer	Dec 03 '25	Proposed Sale	95.24	40,000	3,809,536		Dec 03 04:31 PM
Freidin Aaron	Chief Financial Officer	Nov 17 '25	Sale	79.20	1,697	134,402	284,077	Nov 19 04:08 PM
ILLUMINA, INC.	10% Owner	Nov 17 '25	Sale	79.85	1,000,000	79,850,000	3,502,126	Nov 18 09:33 PM
Aaron Freidin	Officer	Nov 17 '25	Proposed Sale	79.63	1,940	154,482		Nov 14 06:15 PM

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

M.S.H.SDr. Joshua J. Ofman M.D.

CFO & Head of Corporate DevelopmentMr. Aaron Freidin

AdvisorMr. Robert P. Ragusa

Senior Vice President of Global Development & OperationsMr. Paul Ciccolella

Chief Technology OfficerDr. Satnam Alag Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRAL

GRAIL Inc

Upgrade your Finviz experience